Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced that its compensation committee granted an inducement stock option to Daniel Keefe, the company's recently hired Commercial Director for the Western U.S. The grant, made on May 5, 2026, was a material inducement for Keefe to join Aclarion and aligns with Nasdaq Listing Rule 5635(c)(4).
The option allows Keefe to purchase 17,000 shares of Aclarion's common stock at an exercise price of $3.20 per share, equal to the closing price on the grant date. Vesting begins one year after the vesting commencement date with one-fourth of the options vesting, followed by equal monthly installments over three years, contingent on continued employment. The option carries a 10-year term.
This expansion of the commercial team underscores increasing demand for Aclarion's Nociscan platform, which leverages biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain. The company reports triple-digit growth in utilization of Nociscan, a SaaS platform that uses magnetic resonance spectroscopy (MRS) data from MRI machines to noninvasively distinguish between painful and nonpainful discs in the lumbar spine. By extracting and quantifying chemical biomarkers associated with disc pain, Nociscan provides critical insights that can optimize treatment strategies and improve success rates.
The appointment of a dedicated commercial director for the Western U.S. signals Aclarion's commitment to expanding its market presence in a region that represents a significant opportunity for addressing chronic low back pain, a condition affecting millions. With triple-digit utilization growth, the company appears to be gaining traction among healthcare providers seeking better diagnostic tools for a condition that often leads to costly and ineffective treatments.
For more information about Aclarion and its Nociscan platform, visit www.aclarion.com. The company's latest news and updates are available at its newsroom: https://tinyurl.com/aconnewsroom.
The implications of this announcement extend beyond the company itself. As chronic low back pain remains a leading cause of disability worldwide, tools like Nociscan could reduce healthcare costs by enabling more targeted treatments, such as disc surgery or injections, only for painful discs. The expansion of the commercial team suggests that Aclarion is positioning itself to capture a larger share of this market, potentially benefiting patients and payers alike.
